Abstract
Background: The Sudden Cardiac Death in Heart Failure trial showed a significant increase in mortality with amiodarone in patients with an EF of 35% or less and NYHA class III symptoms. Although this finding is not consistent with the results of clinical trials of amiodarone in patients with heart failure, it is not clear how many patients with an EF of 35% or less and NYHA class III symptoms were included in those trials. We conducted this analysis to specifically examine the effect of amiodarone on the survival of such patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
